RNA-based cancer vaccines have emerged as transformative immunotherapeutic platforms, leveraging advances in mRNA technology and personalized medicine approaches. Recent clinical breakthroughs, particularly the success of mRNA-4157 combined with pembrolizumab in melanoma patients, have demonstrated significant improvements in efficacy, with a 44% reduction in recurrence risk compared to checkpoint inhibitor monotherapy. Breakthrough results from pancreatic cancer vaccines and novel glioblastoma treatments using layered nanoparticle delivery systems mark 2024–2025 as a pivotal period for RNA cancer vaccine development. Current RNA vaccine platforms include conventional mRNA, self-amplifying RNA, trans-amplifying RNA, and emerging circular RNA technologies, with over 120 clinical trials currently underway across various malignancies. Critical advances in delivery optimization include next-generation lipid nanoparticles with tissue-specific targeting and novel nanoengineered systems achieving rapid immune system reprogramming. Manufacturing innovations focus on automated platforms, reducing production timelines from nine weeks to under four weeks for personalized vaccines, while costs remain challenging at over $ 100,000 per patient. Artificial intelligence integration is revolutionizing neoantigen selection through advanced algorithms and CRISPR-enhanced platforms, while regulatory frameworks are evolving with new FDA guidance for therapeutic cancer vaccines. Non-coding RNA applications, including microRNA and long non-coding RNA therapeutics, represent emerging frontiers with potential for enhanced immune modulation. With over 60 candidates in clinical development and the first commercial approvals anticipated by 2029, RNA cancer vaccines are positioned to become cornerstone therapeutics in personalized oncology, offering transformative hope for cancer patients worldwide.
基于RNA的癌症疫苗已成为变革性的免疫治疗平台，其发展得益于mRNA技术和个体化医疗方法的进步。近期临床突破性进展，特别是mRNA-4157联合帕博利珠单抗在黑色素瘤患者中取得的成功，显示出疗效的显著提升——与单用检查点抑制剂相比，复发风险降低44%。胰腺癌疫苗的突破性成果以及采用分层纳米颗粒递送系统的新型胶质母细胞瘤治疗方案，标志着2024-2025年将成为RNA癌症疫苗发展的关键时期。当前RNA疫苗平台包括传统mRNA、自扩增RNA、反式扩增RNA以及新兴的环状RNA技术，目前已有超过120项临床试验在不同恶性肿瘤中开展。递送系统优化的关键进展包括具有组织特异性靶向功能的下一代脂质纳米颗粒，以及可实现免疫系统快速重编程的新型纳米工程系统。制造工艺创新聚焦自动化平台，将个体化疫苗生产周期从九周缩短至四周以内，但每位患者超过10万美元的成本仍是当前挑战。人工智能通过先进算法和CRISPR增强平台正在革新新抗原筛选技术，监管框架也随着FDA针对治疗性癌症疫苗的新指南而不断完善。非编码RNA应用领域，包括微小RNA和长链非编码RNA疗法，正成为具有增强免疫调节潜力的新兴前沿。目前已有超过60种候选疫苗进入临床开发阶段，首批商业化批准预计在2029年前实现，RNA癌症疫苗有望成为个体化肿瘤治疗的基石疗法，为全球癌症患者带来变革性希望。
Current Progress and Future Perspectives of RNA-Based Cancer Vaccines: A 2025 Update
肿瘤(癌症)患者之家